In the Specification

Please replace paragraph 1, beginning on page 1, line 6 of the subject application pursuant to 37 C.F.R. § 1.121 as follows:

> This application is a continuation of U.S. Serial No. 08/464,364, filed June 5, 1995, now U.S. Patent No. 6,410,516 issued June 25, 2002, which is a divisional of U.S. Serial No. 08/418,266, filed April 6, 1995, now U.S. Patent No. 5,804,374, issued September 8, 1998, which is a continuation of U.S. Serial No. 07/791,898, filed November 13, 1991, which is a continuation-in-part of ~~U.S. Serial No. 06/946,365, filed December 24, 1986, and a continuation-in-part of U.S. Serial No. 07/318,901, filed March 3, 1989, and of U.S. Serial No. 07/162,680, filed March 1, 1988, and of~~ U.S. Serial No. 07/341,436, filed April 21, 1989~~, and of U.S. Serial No. 06/817,441, filed January 9, 1986, and of U.S. Serial No. 07/155,207, filed February 12, 1988 and of U.S. Serial No. 07/280,173, filed December 5, 1988~~ the contents of all ~~ten~~ referenced applications ~~of which~~ are hereby incorporated by reference.

Please delete the paragraph on page 22, lines 19-20.

Please amend the paragraph starting on page 64, line 29 as follows:

> The inhibitor fraction was treated with trypsin to test whether IκB is a protein (Figure 35B). Tryptic digestion was stopped by the addition of bovine pancreas trypsin inhibitor (BPTI) and samples were analyzed for NF-κB

inhibition. Trypsin treatment interfered with the activity of IκB, as shown by the complete inability of the treated sample to inhibit NF-κB activity (Figure 35B, compare lanes 1 and 6). Trypsin that had been treated with BPTI had no effect (Fig. 35B, lane 5), demonstrating that the inactivation of IκB was specifically caused by the proteolytic activity of trypsin. It appears that IκB requires an intact polypeptide structure for its activity. ~~The nucleotide sequence of the IκB-α gene and the amino acid sequence of IκB-α are shown in Figure 43.~~